Aprea Therapeutics, Inc. - Special Call Transcript
Hello, and welcome to the Aprea Therapeutics Virtual R&D Day. I am Greg Korbel, Vice President of Business Development. On behalf of Aprea Therapeutics, I'm pleased to have you join us for today's presentation and discussion of continued progress in our development pipeline of mutant p53 reactivators.
Please note that the press release we issued earlier today is available on the Investor Relations section of our website, aprea.com. In addition, the slide deck for this webcast as well as a replay of this webcast will be available on the Investor Relations section of our website upon conclusion of the event.
I would like to point out that both our presentation and answers to questions during today's event will contain forward-looking statements. As such, please refer to Slide 2 of today's presentation and to our periodic filings with the SEC for a description of the risks and uncertainties associated with our business. These filings may be accessed through the Investors section of our website or found on sec.gov.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |